Dopaminergic antiparkinsonism agents

Dopaminergic antiparkinsonism agents aim to replace dopamine or prevent the degradation of dopamine. Antiparkinson drugs that aim to replace dopamine in the central nervous system, either release dopamine or mimic the action of dopamine. Drugs that replace dopamine are generally given with peripherally acting dopa carboxylase inhibitors, to prevent the metabolism of levodopa to dopamine peripherally. Dopamine receptor agonists bind to dopamine receptors and mimic the action of dopamine. Selective monoamine oxidase (MAO-B) inhibitors bind to the enzyme MAO-B and prevent dopamine from being broken down. Antiparkinson agents are used to treat Parkinson's disease, which is a degenerative disorder of movement that occurs due to dopamine deficiency in the brain, particularly in the basal ganglia.